D-Cycloserine Augmentation of Intermittent Theta Burst Stimulation (iTBS) in Depression (COGENT)
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to investigate if the drug D-Cycloserine (DCS) improves
the antidepressant effects of Intermittent Theta Burst Stimulation (iTBS), a non-invasive
brain stimulation therapy, in patients with Major Depressive Disorder (MDD). The main
questions it aims to answer are:
- Whether taking DCS prior to iTBS therapy will be more effective in improving depressive
symptoms than iTBS therapy alone.
- Compare the effect of DCS 100mg/day versus 50mg/day on depressive symptoms.
- Test the safety and tolerability of DCS. Participants will take either 50mg DCS per day,
100mg DCS or placebo prior to each iTBS treatment session. iTBS treatment will be
administered daily, 5 days a week for 4 weeks. Clinical measures will be conducted at
baseline and at the ends of weeks 1, 2, 3 and 4 of treatment.
Phase:
Phase 2
Details
Lead Sponsor:
The Alfred
Collaborators:
Blue Bell Health, Australia Gold Coast Hospital and Health Service